December 8, 2025 5:00pm

Indexes’ slip, while C&GT sector stay’s positive waiting for Fed’s meeting this week

Financing: Wave Life Sciences (WVE) Proposes $250 M Offering and Pre-Funded Warrants. Jefferies, Leerink Partners and BofA Securities are acting as joint book-running managers for the offering. Why not after obesity trial news <below>

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

It’s not always time to buy or sell; but it is time to KNOW and why!

Never leave an investor uninformed!  

News: Wave Life Sciences (WVE +$11.03 or +147.26 to $18.52) promising results for an entirely new mechanism drug turns off the gene that produces the activin E protein. Activin E plays a role in fat utilization and energy balance. Earlier results showed turning off the INHBE gene led to activin E reductions of 56% to 85%, depending on the dosage. WVE said that led to a 9.2% reduction in visceral fat and a 4% reduction in total fat mass. Bullishly, patients also had a 0.9% increase in lean mass and a 0.9% decrease in total mass. The results are promising for targeted fat loss, which could ultimately improve body composition. Other means of losing weight — including GLP-1 drugs — don't discriminate. Patients lose fat and lean mass alike. <IBD>

Monday’s RMi Pre-opening: Moving … https://www.regmedinvestors.com/articles/14220

Sunday’s RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is PACKING the Pig that’s Broke … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed DOWN -215.67 points or -0.45%, the S&P closed DOWN -23.89 points or -0.35% while the Nasdaq closed DOWN -32.224 points or -0.14%

  • Theme of the session: indexes weighted by sentiment

Monday’s (my) 40-company covered sector’s advance/decline line opened positive with 26 incliners, 13 decliners and 1 flat ending with a positive close of 22 incliners, 16 decliners and 2 flat

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • Markets are on the lookout for risks to almost-total confidence that the Fed will cut interest rates at its two-day policy meeting, which starts on Tuesday.

The C&GT sector closed positive while the CBOE Fear (VIX) index closed at 16.55 after Friday’s 15.32, Thursday’s 15.79, Wednesday’s 16.08, Tuesday’s 16.57 and last Monday’s 17.34

Metrics:  Monday …

  • The RUT was down -0.50 points or -0.02%,
  • The XLV was down -1.83 points or -1.19%,
  • The NBI was down -17.25 points or -0.30%;
  • The XBI was up +0.25 points or +0.20%
  • The IWM was up +0.10 or +0.04%;
  • The IBB was down -1.21 points or -0.71%,
  • The VIX was up +1.24 points or +8.05% at to 16.55

 

Q4 – December – 3 positive and 3 negative closes

  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Monday Closing UP (10 of 22)

  • WVE Life Sciences (WVE +$11.03),
  • Arrowhead Pharma (ARWR +$1.76 after Friday’s -$3.22),
  • Capricor Therapeutics (CAPR +$1.67 after Friday’s +$1.49),
  • Supernus Therapeutics (SUPN +$1.48 after Friday’s +$0.58),
  • Vericel (VCEL +$1.07 after Friday’s -$0.56),
  • BioNTech (BNTX +$1.03 after Friday’s +$0.25),
  • Entrada Therapeutics (TRDA +$0.72 after Friday’s +$0.16),
  • CRISPR Therapeutics (CRSP +$0.48 after Friday’s -$1.30),
  • Prime Medicine (PRME +$0.46),
  • uniQure NV (QURE +$0.44 after Friday’s -$1.41),

Flat (2)

  • Brainstorm Cell Therapeutics (BCLI $0.00 after Friday’s $0.00),
  • Ultragenyx Pharmaceuticals (RARE)

Monday’s Closing DOWN (10 of 16):

  • Alnylam Pharmaceuticals (ALNY -$28.10 after Friday’s -$7.22),
  • Vertex (VRTX -$13.44 after Friday’s -$1.88),
  • AxoGen (AXGN -$2.53 after Friday’s +$0.47),
  • IQVIA Holdings (IQV -$2.28 after Friday’s +$0.93),
  • BioLife Solutions (BLFS -$0.51 after Friday’s -$0.37),
  • Sarepta Therapeutics (SRPT -$0.40 after Friday’s -$0.56)
  • MiMedx (MDXG -$0.25 after Friday’s +$0.07),
  • Compass Therapeutics (CMPX -$0.17),
  • Intellia Therapeutics (NTLA -$0.17),
  • Ionis Pharmaceuticals IONS -$0.17)

 

The Bottom Line: More of the … WHYs

Skimming the trim …

  • The S&P 500 slipped, its 2nd loss in the last 11 days, the Dow dropped and the Nasdaq dropped down as well.

Most C&GT sector equities shot-up after Friday’s dive, after popping Thursday after Wednesday ++ following “taking a licking” on Tuesday and Monday’s.

  • WAIT, the downslide is coming: I’d go after Capricor Therapeutics (CAPR)!

Take it a session at a time … the REAL question is … how long will this sentiment and conviction “run” last?

 

A question does NOT answer an inquiry; investors need more than a few catalysts that could revive a rally, I do NOT expect end end-of-year flurry!

  • Depleted market valuations and the uncertain payoff from heavy spending as we get closer to 2025 ends and then coming Q4 and FY25 financial and achievement results

 

2nd December week:

  • 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat

Last week,  

  • 12/5 – Friday closed negative with 13 positive, 26 negative and 1 flat
  • 12/4 – Thursday closed positive with 26 positive, 12 negative and 2 flats
  • 12/3 – Wednesday closed positive with 35 positive, 4 negative and 1 flat
  • 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
  • 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

A real question, are cell and gene therapy (C&GT) sector companies with high insider ownership present … opportunity?

  • Do they often demonstrate alignment between management and shareholder interests … a critical factor in navigating volatile market conditions?
  • I will be looking into this …! Stay tuned.

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Monday: Wave Life Sciences (WVE), Arrowhead Pharma (ARWR) and Capricor Therapeutics (CAPR)
  • Friday: Moderna (MRNA), Capricor Therapeutics (CAPR) and IQVIA Holdings (IQV)

The worst three (3) in the session:

  • Monday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and AxoGen (AXGN),
  • Friday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharma (ARWR) and Vertex (VRTX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.